Product
Recombinant anti-HER2 humanized monoclonal antibody
1 clinical trial
1 indication
Indication
Breast Cancer (HER2-positive)Clinical trial
Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-01-13